G&E Herbal Biotechnology Co., Ltd.(TW:4911)
NT$25.00-0.30 (-1.19%)
TW:4911
G&E Herbal Biotechnology Co., Ltd. financials statements
NT$25.00
At close:-0.30 (-1.19%)
G&E Herbal Biotechnology Co., Ltd. (4911) Ratios
G&E Herbal Biotechnology Co., Ltd. Ratios
TW:4911's free cash flow for Q2 2026 was NT$3.46M. For the 2026 fiscal year, TW:4911's free cash flow was decreased by NT$-493.00K and operating cash flow was NT$3.95M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 10.09 | 3.61 | 2.97 | 2.54 | 15.66 |
| Quick Ratio | 9.55 | 3.44 | 2.78 | 2.27 | 13.37 |
| Cash Ratio | 1.67 | 1.22 | 1.18 | 1.25 | 1.41 |
| Solvency Ratio | 3.18 | 0.89 | 0.68 | 0.18 | -1.22 |
| Operating Cash Flow Ratio | 1.49 | 1.08 | 0.96 | 1.09 | -1.06 |
| Short-Term Operating Cash Flow Coverage | 11.53 | 21.22 | 32.88 | 15.65 | -3.51 |
| Net Current Asset Value | NT$ 427.54M | NT$ 325.27M | NT$ 232.31M | NT$ 140.75M | NT$ 127.22M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.05 | 1.15 | 1.16 | 1.13 | 1.01 |
| Debt Service Coverage Ratio | 23.50 | 17.61 | 23.66 | 2.63 | -4.55 |
| Interest Coverage Ratio | 5251.76 | 2918.20 | 20171.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.11 | 0.14 | 0.09 | 0.11 | 0.05 |
| Net Debt to EBITDA | -0.44 | -1.07 | -1.34 | -6.52 | 0.95 |
| Profitability Margins | |||||
| Gross Profit Margin | 83.98% | 82.46% | 79.69% | 60.91% | 39.17% |
| EBIT Margin | 49.27% | 50.10% | 49.88% | 11.19% | -79.61% |
| EBITDA Margin | 52.70% | 54.27% | 55.02% | 25.73% | -41.61% |
| Operating Profit Margin | 49.27% | 48.04% | 44.47% | 11.19% | -79.61% |
| Pretax Profit Margin | 51.24% | 50.08% | 49.88% | 11.19% | -74.16% |
| Net Profit Margin | 45.03% | 40.98% | 39.90% | 11.42% | -80.92% |
| Continuous Operations Profit Margin | 45.03% | 40.98% | 39.90% | 11.42% | -80.92% |
| Net Income Per EBT | 87.88% | 81.83% | 80.00% | 102.13% | 109.12% |
| EBT Per EBIT | 104.00% | 104.25% | 112.17% | 100.00% | 93.16% |
| Return on Assets (ROA) | 14.27% | 10.64% | 8.20% | 0.94% | -2.87% |
| Return on Equity (ROE) | 15.00% | 12.24% | 9.49% | 1.07% | -2.91% |
| Return on Capital Employed (ROCE) | 16.41% | 14.34% | 10.55% | 1.05% | -2.86% |
| Return on Invested Capital (ROIC) | 14.31% | 11.63% | 8.40% | 1.04% | -2.85% |
| Return on Tangible Assets | 16.52% | 12.36% | 9.66% | 1.14% | -3.57% |
| Earnings Yield | 5.50% | 3.58% | 2.46% | 0.31% | -1.58% |
| Efficiency Ratios | |||||
| Receivables Turnover | 17.86 | 13.87 | 12.28 | 84.01 | 4.80 |
| Payables Turnover | 34.23 | 21.92 | 64.10 | 9.79 | 133.45 |
| Inventory Turnover | 1.96 | 2.01 | 1.61 | 1.02 | 0.75 |
| Fixed Asset Turnover | 0.84 | 0.67 | 0.48 | 0.17 | 0.06 |
| Asset Turnover | 0.32 | 0.26 | 0.21 | 0.08 | 0.04 |
| Working Capital Turnover Ratio | 0.82 | 0.89 | 0.97 | 0.48 | 0.19 |
| Cash Conversion Cycle | 196.17 | 191.03 | 250.87 | 323.27 | 557.56 |
| Days of Sales Outstanding | 20.43 | 26.32 | 29.73 | 4.34 | 76.12 |
| Days of Inventory Outstanding | 186.40 | 181.36 | 226.83 | 356.20 | 484.18 |
| Days of Payables Outstanding | 10.66 | 16.65 | 5.69 | 37.28 | 2.74 |
| Operating Cycle | 206.83 | 207.68 | 256.56 | 360.54 | 560.29 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.10 | 2.28 | 1.93 | 1.80 | -0.17 |
| Free Cash Flow Per Share | 1.05 | 2.18 | 1.83 | 1.74 | -0.20 |
| Dividend Paid and CapEx Coverage Ratio | 1.47 | 3.57 | 20.57 | 33.69 | -4.63 |
| Capital Expenditure Coverage Ratio | 21.92 | 22.75 | 20.57 | 33.69 | -4.63 |
| Operating Cash Flow Coverage Ratio | 10.09 | 16.64 | 20.90 | 15.65 | -3.51 |
| Operating Cash Flow to Sales Ratio | 0.23 | 0.54 | 0.63 | 1.55 | -0.37 |
| Free Cash Flow Yield | 2.65% | 4.52% | 3.67% | 4.03% | -0.89% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 18.22 | 27.90 | 40.63 | 332.23 | -66.62 |
| Price-to-Sales (P/S) Ratio | 8.19 | 11.44 | 16.21 | 37.21 | 51.31 |
| Price-to-Book (P/B) Ratio | 2.73 | 3.42 | 3.85 | 3.48 | 1.84 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 37.79 | 22.13 | 27.25 | 24.78 | -112.78 |
| Price-to-Operating Cash Flow Ratio | 36.07 | 21.15 | 25.92 | 24.05 | -137.17 |
| Price-to-Earnings Growth (PEG) Ratio | 0.70 | 0.69 | 0.05 | -2.40 | -1.85 |
| Enterprise Value Multiple | 15.10 | 20.00 | 28.12 | 138.07 | -122.36 |
| Enterprise Value | 2.46B | 2.70B | 2.81B | 2.30B | 1.25B |
| EV to EBITDA | 15.10 | 20.00 | 28.12 | 138.07 | -122.36 |
| EV to Sales | 7.96 | 10.86 | 15.47 | 35.53 | 50.92 |
| EV to Free Cash Flow | 36.72 | 21.01 | 26.01 | 23.67 | -111.92 |
| EV to Operating Cash Flow | 35.05 | 20.07 | 24.74 | 22.96 | -136.12 |
| Tangible Book Value Per Share | 12.48 | 11.87 | 10.69 | 9.99 | 9.84 |
| Shareholders’ Equity Per Share | 14.56 | 14.13 | 12.97 | 12.41 | 12.28 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.12 | 0.18 | 0.20 | -0.02 | -0.09 |
| Revenue Per Share | 4.85 | 4.22 | 3.08 | 1.16 | 0.44 |
| Net Income Per Share | 2.18 | 1.73 | 1.23 | 0.13 | -0.36 |
| Tax Burden | 0.88 | 0.82 | 0.80 | 1.02 | 1.09 |
| Interest Burden | 1.04 | 1.00 | 1.00 | 1.00 | 0.93 |
| Research & Development to Revenue | 0.11 | 0.14 | 0.14 | 0.22 | 0.51 |
| SG&A to Revenue | 0.24 | 0.20 | 0.22 | 0.30 | 0.68 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.44 | 1.08 | 1.25 | 13.83 | 0.46 |
Currency in TWD
